Butyrylcholinesterase: An important new target in Alzheimer's disease therapy

Nigel H. Greig, Debomoy K. Lahiri, Kumar Sambamurti

Research output: Contribution to journalArticle

210 Citations (Scopus)

Abstract

Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine (ACh) levels. However, BuChE activity progressively increases in patients with Alzheimer's disease (AD), while AChE activity remains unchanged or declines. Both enzymes therefore represent legitimate therapeutic targets for ameliorating the cholinergic deficit considered to be responsible for the declines in cognitive, behavioral and global functioning characteristic of AD. The two enzymes differ in substrate specificity, kinetics and activity in different brain regions. Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, rivastigmine, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias. Recent evidence suggests that both AChE and BuChE may have roles in the aetiology and progression of AD beyond regulation of synaptic ACh levels. The development of specific BuChE inhibitors and further experience with the dual enzyme inhibitor rivastigmine will improve understanding of the aetiology of AD and should lead to a wider variety of potent treatment options.

Original languageEnglish (US)
Pages (from-to)77-91
Number of pages15
JournalInternational Psychogeriatrics
Volume14
Issue numberSUPPL. 1
DOIs
StatePublished - Dec 1 2002

Fingerprint

Butyrylcholinesterase
Alzheimer Disease
Rivastigmine
Acetylcholinesterase
Therapeutics
Acetylcholine
Brain
Cholinesterase Inhibitors
Enzyme Inhibitors
Enzymes
Substrate Specificity
Cholinergic Agents
Dementia

Keywords

  • Acetylcholinesterase
  • Alzheimer's disease
  • Beta-amyloid
  • Butyrylcholinesterase
  • Cholinesterase inhibitor
  • Cymserine
  • Donepezil
  • Galantamine
  • Rivastigmine
  • Tacrine

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Aging
  • Psychiatry and Mental health
  • Psychology(all)
  • Clinical Psychology

Cite this

Butyrylcholinesterase : An important new target in Alzheimer's disease therapy. / Greig, Nigel H.; Lahiri, Debomoy K.; Sambamurti, Kumar.

In: International Psychogeriatrics, Vol. 14, No. SUPPL. 1, 01.12.2002, p. 77-91.

Research output: Contribution to journalArticle

Greig, Nigel H. ; Lahiri, Debomoy K. ; Sambamurti, Kumar. / Butyrylcholinesterase : An important new target in Alzheimer's disease therapy. In: International Psychogeriatrics. 2002 ; Vol. 14, No. SUPPL. 1. pp. 77-91.
@article{c938175765eb44ed83e42e86d8abe854,
title = "Butyrylcholinesterase: An important new target in Alzheimer's disease therapy",
abstract = "Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine (ACh) levels. However, BuChE activity progressively increases in patients with Alzheimer's disease (AD), while AChE activity remains unchanged or declines. Both enzymes therefore represent legitimate therapeutic targets for ameliorating the cholinergic deficit considered to be responsible for the declines in cognitive, behavioral and global functioning characteristic of AD. The two enzymes differ in substrate specificity, kinetics and activity in different brain regions. Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, rivastigmine, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias. Recent evidence suggests that both AChE and BuChE may have roles in the aetiology and progression of AD beyond regulation of synaptic ACh levels. The development of specific BuChE inhibitors and further experience with the dual enzyme inhibitor rivastigmine will improve understanding of the aetiology of AD and should lead to a wider variety of potent treatment options.",
keywords = "Acetylcholinesterase, Alzheimer's disease, Beta-amyloid, Butyrylcholinesterase, Cholinesterase inhibitor, Cymserine, Donepezil, Galantamine, Rivastigmine, Tacrine",
author = "Greig, {Nigel H.} and Lahiri, {Debomoy K.} and Kumar Sambamurti",
year = "2002",
month = "12",
day = "1",
doi = "10.1017/S1041610203008676",
language = "English (US)",
volume = "14",
pages = "77--91",
journal = "International Psychogeriatrics",
issn = "1041-6102",
publisher = "Cambridge University Press",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Butyrylcholinesterase

T2 - An important new target in Alzheimer's disease therapy

AU - Greig, Nigel H.

AU - Lahiri, Debomoy K.

AU - Sambamurti, Kumar

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine (ACh) levels. However, BuChE activity progressively increases in patients with Alzheimer's disease (AD), while AChE activity remains unchanged or declines. Both enzymes therefore represent legitimate therapeutic targets for ameliorating the cholinergic deficit considered to be responsible for the declines in cognitive, behavioral and global functioning characteristic of AD. The two enzymes differ in substrate specificity, kinetics and activity in different brain regions. Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, rivastigmine, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias. Recent evidence suggests that both AChE and BuChE may have roles in the aetiology and progression of AD beyond regulation of synaptic ACh levels. The development of specific BuChE inhibitors and further experience with the dual enzyme inhibitor rivastigmine will improve understanding of the aetiology of AD and should lead to a wider variety of potent treatment options.

AB - Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine (ACh) levels. However, BuChE activity progressively increases in patients with Alzheimer's disease (AD), while AChE activity remains unchanged or declines. Both enzymes therefore represent legitimate therapeutic targets for ameliorating the cholinergic deficit considered to be responsible for the declines in cognitive, behavioral and global functioning characteristic of AD. The two enzymes differ in substrate specificity, kinetics and activity in different brain regions. Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, rivastigmine, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias. Recent evidence suggests that both AChE and BuChE may have roles in the aetiology and progression of AD beyond regulation of synaptic ACh levels. The development of specific BuChE inhibitors and further experience with the dual enzyme inhibitor rivastigmine will improve understanding of the aetiology of AD and should lead to a wider variety of potent treatment options.

KW - Acetylcholinesterase

KW - Alzheimer's disease

KW - Beta-amyloid

KW - Butyrylcholinesterase

KW - Cholinesterase inhibitor

KW - Cymserine

KW - Donepezil

KW - Galantamine

KW - Rivastigmine

KW - Tacrine

UR - http://www.scopus.com/inward/record.url?scp=0036993145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036993145&partnerID=8YFLogxK

U2 - 10.1017/S1041610203008676

DO - 10.1017/S1041610203008676

M3 - Article

C2 - 12636181

AN - SCOPUS:0036993145

VL - 14

SP - 77

EP - 91

JO - International Psychogeriatrics

JF - International Psychogeriatrics

SN - 1041-6102

IS - SUPPL. 1

ER -